Dexmedetomidine Preemptive Analgesia on Intra- and Postoperative Pain in Noncardiac Surgery: A Randomized, Double-Blind, Controlled Study.
Xiaohua Wang, Haosheng Chang, Wenwei Qi et al.
✦ AI-curated · Sources linked
In 30 seconds
This single-center, double-blind randomized controlled trial evaluated preemptive intravenous dexmedetomidine in 220 patients undergoing noncardiac surgery. Dexmedetomidine was given from 15 minutes before anesthesia induction until 15 minutes afterward and compared with saline. Intraoperative nociception-index compliance was higher with dexmedetomidine (90.7% vs 12.5%; P < .001). Moderate-to-severe postoperative pain was also less frequent at each assessed time point, including 2.8% vs 25.9% at 0 hour. The dexmedetomidine group had lower rescue opioid consumption and postoperative nausea and vomiting, with favorable reported safety profiles.
Key findings
- Intraoperative NOX compliance was 90.7% with dexmedetomidine versus 12.5% with placebo (P < .001).
- Moderate-to-severe pain at 0 hour occurred in 2.8% versus 25.9%; rates were lower with dexmedetomidine at all assessed postoperative time points.
- Dexmedetomidine reduced rescue opioid consumption (z = -2.428, P = .004) and mPONV (z = -4.901, P = .001).
- The authors reported improved hemodynamic stability and favorable safety profiles with dexmedetomidine.
Why it matters
The findings suggest that a brief pre-induction dexmedetomidine infusion can improve both an objective intraoperative nociception measure and postoperative pain outcomes in this trial population. The accompanying reductions in rescue opioid use and nausea and vomiting are relevant to perioperative recovery, although the results come from a single-center study and do not establish effects across all surgical settings.
What to keep in mind
The trial was conducted at a single center; the abstract does not report longer-term outcomes beyond 7 days.